James Sapirstein was named Chief Executive Officer of Cocrystal Pharma, Inc. As of November 7, 2026, Cocrystal Pharma, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from June 9, 2026 to August 18, 2026, naming 2 appointments (Form 8-K, June 9, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Cocrystal Pharma, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Cocrystal Pharma, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-06-09 to 2026-08-18. They name 2 people. Every row below is cited to the filing it comes from, and this page adds each new change as Cocrystal Pharma, Inc. files it.
Also on the record for Cocrystal Pharma, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 6, 2026 | Stake report, Schedule 13D/A, by OPKO HEALTH, INC. | 29.6% of the class | 5%+ stakes | Source |
| August 7, 2026 | Stake report, Schedule 13D, by OPKO HEALTH, INC. | 29.6% of the class | 5%+ stakes | Source |
| August 7, 2026 | Stake report, Schedule 13D/A, by Phillip Frost, M.D. | 13.9% of the class | 5%+ stakes | Source |
| October 30, 2025 | Stake report, Schedule 13D/A, by Phillip Frost, M.D. | 17.8% of the class | 5%+ stakes | Source |
| October 2, 2025 | Stake report, Schedule 13D/A, by Phillip Frost, M.D. | 10.6% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Cocrystal Pharma, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Cocrystal Pharma, Inc. and the records around it.
Cocrystal Pharma, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- Phillip Frost, M.D. also filed stake reports on 3 other companies: Safe Pro Group Inc. (Sep 2026), Fluent, Inc. (Jan 2026)
Watch Cocrystal Pharma, Inc.
Get an email when Cocrystal Pharma, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Cocrystal Pharma, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Cocrystal Pharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Cocrystal Pharma, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-08-18 | In | Director | 8-K, 2026-08-18 | ||
| 2026-06-09 | In | Chief Executive Officer | 8-K, 2026-06-09 |
Who leads Cocrystal Pharma, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Carol L. Brosgart, appointed (filed 2026-08-18).
- Chief Executive Officer: James Sapirstein, appointed (filed 2026-06-09).
New leaders reset buying decisions — get the Full Report on Cocrystal Pharma, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Cocrystal Pharma, Inc., with the record behind each one.
Find candidates like Director at Cocrystal Pharma, Inc.Every change, in the filing's words
Appointed: Carol L. Brosgart, Director
(d) On August 12, 2026, the Board of Directors (the "Board") of Cocrystal Pharma, Inc. (the "Company") appointed Carol L. Brosgart as a director of the Company, effective immediately.
Appointed: James Sapirstein, Chief Executive Officer
On June 3, 2026, the Board of Directors (the "Board") of Cocrystal Pharma, Inc. (the "Company") appointed James Sapirstein as the Chief Executive Officer of the Company, effective immediately, pursuant to the terms of an employment offer letter (the "Offer Letter").
- Pursuant to the Offer Letter, Mr. Sapirstein is entitled to the following: (i) an initial annual base salary of $265,000; and (ii) an annual performance bonus equal to 50% of his base salary, based upon the achievement of performance targets established by the Board.
- In addition, Mr. Sapirstein received an initial grant of 10-year stock options to purchase 235,000 shares of the Company's common stock under the Company's 2025 Equity Incentive Plan (the "Option Grant").
- The Option Grant is exercisable at an exercise price of $1.05, which represents the closing price of the Company's common stock on the date of grant, and vests in four equal annual installments beginning on June 3, 2027, subject to Mr. Sapirstein's continued employment with the Company.
- In the event of a Change in Control (as defined in the Offer Letter), the Option Grant shall accelerate and vest in full.
- In the event of a termination without Cause (as defined in the Offer Letter), 50% of the then unvested options under the Option Grant shall accelerate and become fully vested upon such termination.
Tools for this story
Each opens in a new tab, filled in for Cocrystal Pharma, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.